Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330990 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03330990 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 15 participants.
The verdict
NCT03330990, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
Interventions
- DRUG Entrectinib
- DRUG Midazolam Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2018-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330990
The ClinicalTrials.gov registry entry for NCT03330990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entrectinib is the first listed.
NCT03330990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330990 about?
NCT03330990 is a clinical study titled "Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients". This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
What is the current status of trial NCT03330990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-11-14. Estimated completion is 2018-07-11.
What interventions are being tested in trial NCT03330990?
The interventions under investigation include: Entrectinib (DRUG), Midazolam Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03330990?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.